Background and aims: Minimisation of the placebo responses in randomised controlled trials [RCTs] is essential for efficient evaluation of new interventions. Placebo rates have been high in ulcerative colitis [UC] clinical trials, and factors influencing this are poorly understood. We quantify placebo response and remission rates in UC RCTs and identify trial design factors influencing them.


Placebo Effect, Maintenance Therapy, Anti-Inflammatory Agents Non-Steroidal, MCS, RCT, Induction Chemotherapy, Drug Therapy, DAI, Ulcerative Colitis, Disease Activity Index, therapeutic use, Mayo Clinic Score, Immunosuppressive Agents, Randomised controlled trial, Treatment Outcome

Read More